International Assets Investment Management LLC Has $405,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

International Assets Investment Management LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 99.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 566 shares of the biopharmaceutical company's stock after selling 880,373 shares during the quarter. International Assets Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Adirondack Trust Co. increased its position in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock valued at $453,000 after purchasing an additional 10 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after buying an additional 10 shares during the last quarter. Trust Co. of Vermont lifted its position in Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company's stock worth $165,000 after buying an additional 12 shares during the last quarter. Brighton Jones LLC grew its position in Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company's stock valued at $967,000 after acquiring an additional 14 shares during the last quarter. Finally, Nvwm LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company's stock valued at $1,039,000 after purchasing an additional 14 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on REGN shares. Leerink Partners reissued a "market perform" rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research note on Thursday, October 24th. Leerink Partnrs lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Citigroup started coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a "neutral" rating and a $895.00 price target for the company. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $1,037.33.

Regeneron Pharmaceuticals Stock Down 5.0 %

Shares of NASDAQ REGN traded down $36.71 during midday trading on Friday, reaching $696.88. The company's stock had a trading volume of 1,117,222 shares, compared to its average volume of 755,959. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $751.44 and a 200-day simple moving average of $961.06. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $691.00 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $76.58 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 2.19 and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.